Acurx Pharmaceuticals to Present at the Emerging Growth Conference on August 18, 2021
Acurx Pharmaceuticals, a clinical stage biopharmaceutical company focused on innovative antibiotics, will have its President & CEO, David P. Luci, present at the Emerging Growth Conference on August 18, 2021, at 11:15 a.m. Eastern Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Acurx Pharmaceuticals, a clinical stage biopharmaceutical company focused on innovative antibiotics, will have its President & CEO, David P. Luci, present at the Emerging Growth Conference on August 18, 2021, at 11:15 a.m. Eastern Time. This interactive online event aims to engage current stockholders and the investment community, allowing for potential Q&A. The conference will be webcast live and archived for 30 days on the company's website. Acurx is developing antibiotics targeting hard-to-treat infections, including MRSA and VRE.
Details
News Market Reaction – ACXP
The recorded move for ACXP in the trading session of this news was +0.63%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
STATEN ISLAND, N.Y., Aug. 12, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that David P. Luci, President & CEO, will present at the Emerging Growth Conference as follows:
Date: | Wednesday, August 18, 2021 |
Time: | 11:15 a.m. Eastern Time |
Webcast: | https://goto.webcasts.com/starthere.jsp?ei=1486517&tp_key=3bd9735fe4&sti=acxp |
This live, interactive online event will provide current stockholders and the investment community the opportunity to interact with David P. Luci. As time permits, Mr. Luci may be able to respond to questions from participants.
The presentations will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company's website at www.acurxpharmaceuticals.com, under the Investors section.
About Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D preclinical pipeline includes antibiotic candidates that target other Gram-positive bacteria, including Methicillin-Resistant Staphylococcus aureus (MRSA), Vancomycin-Resistant Enterococcus (VRE) and Penicillin-Resistant Streptococcus pneumoniae (PRSP).
To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.
Investor Contact:
Acurx Pharmaceuticals, Inc.
David P. Luci, President & CEO
Tel: 917-533-1469
Email: davidluci@acurxpharma.com
View original content:https://www.prnewswire.com/news-releases/acurx-pharmaceuticals-to-present-at-the-emerging-growth-conference-on-august-18-2021-301353864.html
SOURCE Acurx Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.